The healthcare divisions of Mubadala and G42, an artificial intelligence and cloud computing technology company, will merge to create an integrated, data-driven and future-ready healthcare company in the UAE.
The merger brings together G42 Healthcare’s medical and data-centric technologies and Mubadala Health’s world-class patient care.
The new entity will seek to revolutionise the regional healthcare landscape and deliver a new approach to personalised, patient-centric care by leveraging the strength of this combined network, which includes state-of-the-art healthcare facilities and digital platforms.
With medical research and innovation at the core of its ambitions, the new company intends to become a vertically integrated healthcare powerhouse. It will deliver pioneering clinical solutions to help solve the world’s most critical health and diagnostic challenges.
Hasan Jasem Al Nowais, Mubadala Health’s chief executive, has been appointed CEO of the new entity and will also continue in his role with Mubadala Health.
Waleed Al Mokarrab Al Muhairi, Chairman of Mubadala Health and Deputy CEO of Mubadala, said, “The future of healthcare lies in the incredible, fast-moving advances being made in technology. For over a decade, Mubadala has invested in the highest standard of patient care for the residents of the UAE across a number of specialities. We now seek to take patient care to the next level, into a new era of precision and personalised medicine.”
Across the two organisations, healthcare assets today include Cleveland Clinic Abu Dhabi; Imperial College London Diabetes Centre; HealthPoint; National Reference Laboratory; HealthPlus; Danat Al Emarat; Moorfields Eye Hospital Abu Dhabi; Biogenix; the UAE’s Omics Centre of Excellence; and Insights Research Organisation & Solutions (IROS), the first UAE-based contract research organisation specialising in healthcare research.
Mubadala Health was launched in January 2021 to integrate a network of world-class healthcare providers. Earlier this year, it also announced a collaboration with the Dubai Health Authority (DHA) and the UAE Ministry of Health and Prevention (MOHAP) to launch a 125,000 square-foot stand-alone day surgery and medical facility in Dubai in Q3 2022. It also has a stake in Al Meswak clinics in Saudi Arabia.
Al Nowais added, “The new company represents a truly integrated healthcare ecosystem where research, technology, AI, and genomics are combined with world-class care to optimise clinical outcomes. We are committed to ensuring that our exceptional team of physicians and caregivers can access pioneering medical technologies and deliver unparalleled patient care.”
Peng Xiao, Group CEO of G42, stated, “We aim to build on the respective strengths of G42 Healthcare and Mubadala Health to unlock healthcare super-intelligence and facilitate global healthcare expansion. Our capabilities and experience in leveraging data and artificial intelligence will allow us to continue transforming the traditional healthcare ecosystem to deliver top-notch patient care, fuelled by the latest breakthrough research – all in world-class facilities.”
While continuing to build its network in the UAE, the new company will consider opportunities for international expansion and new partnerships. The new entity will also focus on collaboration with leading researchers and pharmaceutical and health-tech ecosystems.
Follow us on
